Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06967181) titled 'A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults' on May 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: CyanVac LLC
Condition:
Mumps
Intervention:
Biological: CVM150
Biological: CVM26
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: May 14, 2025
Target Sample Size: 60
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06967181...